Peptide of the Week: Epitalon — 10% Off This Week
Peptide of the Week: Epitalon — 10% Off This Week
Definition: Pinealon is a short synthetic tripeptide made of glutamic acid, aspartic acid, and arginine, commonly written as Glu-Asp-Arg or EDR. In the published literature, it has mainly been studied in relation to neuronal function, oxidative stress, gene expression, and age-related central nervous system research.
Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg, also abbreviated as EDR.
The current evidence base is mostly preclinical, including cell studies, animal models, and mechanistic reviews.
Published research has focused on neuronal viability, oxidative stress, apoptosis-related signaling, and gene expression.
Pinealon is scientifically interesting, but the human evidence base remains limited.
Pinealon is an ultrashort synthetic peptide composed of three amino acids: glutamic acid, aspartic acid, and arginine. Because of this sequence, it is commonly referred to in the literature as the EDR peptide. Public chemistry references list Pinealon under CAS 175175-23-2.
Within the research literature, Pinealon has mainly been explored in brain and nervous system contexts, particularly in studies involving oxidative stress, neuronal cell survival, age-associated CNS changes, and possible gene-regulatory effects. Much of the published literature comes from a relatively narrow body of authors and should be interpreted conservatively.
Pinealon is a very small peptide being researched for how it may affect brain-related cellular signaling. Most interest around it comes from lab and animal work examining oxidative stress, neuronal survival, learning-related processes, and gene expression. The research is intriguing, but still early.
One of the most consistent themes in the literature is Pinealon’s potential role in neuronal cell survival under stress. In cell-based research, Pinealon has been reported to increase viability in cerebellar granule cell cultures while reducing free radical accumulation. This places it within a category of peptides being explored for cellular resilience and oxidative stress modulation.
Animal research has also examined Pinealon in prenatal hyperhomocysteinemia models. In this context, published work reported improvements in certain learning and spatial-orientation measures in offspring, along with reduced reactive oxygen species accumulation and fewer necrotic neurons in isolated cerebellar-cell populations.
Mechanistic reviews have proposed that EDR peptides such as Pinealon may influence transcriptional activity and protein synthesis related to neuronal maintenance and apoptosis-associated pathways. This is one of the more distinctive aspects of the Pinealon literature, although these mechanisms remain investigational and should not be overstated.
Some papers have also described Pinealon within broader aging and CNS-function discussions. These reports suggest possible relevance in age-related biological processes, but the human-facing evidence is limited and not strong enough to support confident real-world claims.
The clearest recurring signal in the research is that Pinealon may reduce oxidative-stress burden in neuronal models. In simple terms, this means researchers are studying whether the peptide helps nerve cells better tolerate damaging reactive oxygen species under stress conditions.
Published mechanistic work suggests Pinealon may influence pathways tied to cell survival, apoptosis regulation, and general neuronal maintenance. Rather than acting through one simple pathway, Pinealon is usually discussed as a small signaling peptide with broader regulatory relevance.
A key feature of the ultrashort peptide literature is the hypothesis that some peptides may interact directly or indirectly with gene-regulatory systems. In Pinealon’s case, this idea has been explored as part of its possible role in neuronal function, protein synthesis, and age-related cellular signaling.
Think of Pinealon as a very small signaling fragment that researchers study to see whether it helps stressed nerve cells stay more stable. The theory is not that it does one large, single action. Instead, it may influence several low-level processes tied to oxidative stress, survival signaling, and gene expression.
Pinealon belongs to a broader category of ultrashort peptides, sometimes called bioregulatory peptides. These compounds have been studied for their potential tissue-specific signaling roles, especially in aging and CNS-related research. In the literature, Pinealon is usually discussed as part of a narrower, more mechanistic scientific tradition rather than the mainstream evidence base seen with better-known peptide categories.
That distinction matters. Pinealon is scientifically interesting, but it is not supported by a deep, large-scale modern clinical literature. The current body of evidence is best described as preliminary, mechanistic, and preclinical.
Pinealon may reduce oxidative stress markers in neuronal models
Pinealon may support neuronal cell viability under laboratory stress conditions
Animal data suggests possible relevance to learning and spatial-performance outcomes in specific models
Mechanistic reviews suggest possible effects on gene expression and protein synthesis
The current human evidence base is limited
Preclinical and mechanistic. The evidence is promising enough to justify scientific interest, but not strong enough for confident therapeutic conclusions.
Most of the literature is preclinical rather than large-scale human clinical research.
Several frequently cited papers come from a relatively narrow author group and research tradition.
Proposed mechanisms involving DNA interaction and transcriptional regulation remain investigational.
Pinealon is best described as a research peptide studied in experimental contexts involving neuronal models, oxidative stress, and age-related CNS questions. For any research peptide, the most relevant quality signals include identity, purity, storage conditions, and batch-level analytical transparency.
That is why educational pages should be supported by clear documentation standards, including:
batch-level analytical review
transparent lab-result practices
storage guidance
certificate-of-analysis literacy
research-only positioning
Relevant Luxara Labs pages for research transparency and documentation include:
Transparency Hub
https://luxaralabs.com/transparency/
Lab Results
https://luxaralabs.com/lab-results/
How to Read a COA
https://luxaralabs.com/how-to-read-a-coa/
Research Standards & Methodology
https://luxaralabs.com/research-standards-methodology/
Peptide Storage and Handling
https://luxaralabs.com/peptide-storage-handling-stability/
Pinealon is drawing attention in peptide research discussions because it sits at the intersection of several active areas of interest:
neuronal stress biology
oxidative-stress regulation
age-related CNS research
gene-expression signaling
ultrashort peptide bioregulation
For researchers who follow niche CNS-oriented peptide literature, Pinealon stands out because of its compact structure and the repeated emphasis on neuroprotective signaling themes in the available research.
Clinical and preclinical studies have demonstrated significant improvements in cognitive metrics:
Memory Retention: Research shows up to a 30% increase in memory retention scores in animal models.
Attention Span: Tasks involving focus and reaction time showed a 50% improvement following administration.
Learning: It has been shown to restore learning capabilities in models of experimental diabetes and prenatal stress.
Pinealon is frequently studied for its “jet lag” or shift-work recovery potential:
Melatonin Optimization: It aids in the restoration of natural sleep-wake cycles.
Sleep Efficiency: Studies indicate reduced sleep onset time and improved sleep architecture.
In geriatric practice, Pinealon is classified as a geroprotector. A study involving patients aged 41–83 showed that Pinealon, often in combination with Vesugen, improved CNS activity and lowered “biological age” markers relative to chronological age.
Note: Pinealon is currently intended for laboratory research purposes.
Common Research Dose: 200 mcg to 10 mg per day, depending on the focus (Cognitive vs. Neuroprotective).
Cycle Duration: Typically administered in 10–20 day “pulses” twice a year in clinical aging studies.
Bioavailability: While many peptides require injection, Pinealon’s short chain allows for high stability; however, subcutaneous injection remains the gold standard for maximum absorption in research settings.
Pinealon is often better understood when viewed alongside other compounds commonly discussed in CNS-adjacent peptide research.
Pinealon is a tripeptide with the sequence EDR. Epitalon is a tetrapeptide with the sequence AEDG. They are different compounds with different proposed mechanisms and different literature bases.
Selank and Semax are more widely recognized in nootropic and neuropeptide discussions. Pinealon is much more niche and is generally discussed in a more mechanistic and age-related bioregulator context.
Cerebrolysin is a peptide mixture with a very different profile and literature base. Pinealon is a defined ultrashort tripeptide. The two should not be treated as interchangeable.
Relevant related guides:
Epitalon: https://luxaralabs.com/epitalon-canada/
Cerebrolysin: https://luxaralabs.com/cerebrolysin-research-canada/
Pinealon is a synthetic tripeptide made of glutamic acid, aspartic acid, and arginine. It is commonly written as Glu-Asp-Arg or EDR.
It is mainly being studied in connection with neuronal stress, oxidative damage, gene-expression regulation, and age-related central nervous system models.
Pinealon is commonly listed under CAS 175175-23-2.
No. Pinealon is EDR, while Epitalon is AEDG. They are distinct peptides with different structures and different research contexts.
No. The evidence base remains limited and is weighted toward cell studies, animal models, and mechanistic reviews.
This should not be stated as fact without stronger primary evidence. The currently available literature does not justify presenting that as a settled conclusion.
Researchers are interested in Pinealon because published work has linked it to oxidative stress, neuronal survival, and possible gene-regulatory effects in CNS-related models.
Peptides in Canada Overview
https://luxaralabs.com/peptides-canada/
Knowledge Hub
https://luxaralabs.com/peptides-canada-knowledge-hub/
Luxara Labs Research Index
https://luxaralabs.com/luxara-labs-research-index/
Peptides 101
https://luxaralabs.com/peptides101/
Research Use Regulations Canada
https://luxaralabs.com/research-use-regulations-canada/
Transparency Hub
https://luxaralabs.com/transparency/
How to Read a COA
https://luxaralabs.com/how-to-read-a-coa/
Lab Results
https://luxaralabs.com/lab-results/
Research Standards & Methodology
https://luxaralabs.com/research-standards-methodology/
Peptide Storage and Handling
https://luxaralabs.com/peptide-storage-handling-stability/
Selank Research Guide
https://luxaralabs.com/selank-canada/
Semax Research Guide
https://luxaralabs.com/semax-canada/
DSIP Research Review
https://luxaralabs.com/dsip-research-review-canada/
Epitalon Research Guide
https://luxaralabs.com/epitalon-canada/
Cerebrolysin Research Guide
https://luxaralabs.com/cerebrolysin-research-canada/
PubChem. Glu-Asp-Arg (CID 10273502).
https://pubchem.ncbi.nlm.nih.gov/compound/Glu-Asp-Arg
Khavinson V, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011.
https://pubmed.ncbi.nlm.nih.gov/21978084/
Arutjunyan A, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine. 2012.
https://pubmed.ncbi.nlm.nih.gov/22567179/
Meshchaninov VN, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology. 2015.
https://pubmed.ncbi.nlm.nih.gov/26390612/
Khavinson V, Linkova N. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. 2020.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7795577/
Khavinson V, et al. Neuroprotective Effects of Tripeptides: Epigenetic Regulators of Gene Expression. International Journal of Molecular Sciences. 2021.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8227791/
Ilina A, et al. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in the Context of Alzheimer’s Disease. International Journal of Molecular Sciences. 2022.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9032300/
Reviewed for research accuracy: This page was prepared as an educational summary of publicly available chemistry records, mechanistic reviews, and published peptide research literature.
Methodology note: Luxara Labs research guides are written to summarize published data, chemistry references, and analytical context. These pages do not provide medical advice, dosing instructions, or therapeutic recommendations.
Research-only notice: All compounds referenced by Luxara Labs are presented strictly in a research context.
Looking for a research-focused source of Pinealon backed by transparent standards, documented handling practices, and a research-first approach?
Explore Luxara Labs’ quality and research resources:
Transparency Hub
https://luxaralabs.com/transparency/
Lab Results
https://luxaralabs.com/lab-results/
How to Read a COA
https://luxaralabs.com/how-to-read-a-coa/
Research Standards & Methodology
https://luxaralabs.com/research-standards-methodology/
Join our list and get an instant 10% discount code — valid for first-time buyers.
